Bayer's Dual Catalyst: A Legal Cliffhanger and a Clinical Comeback

Bayer shares face a pivotal moment with a Supreme Court glyphosate ruling and positive stroke drug trial data. Analysts are divided as the stock rallies.

Bayer shares are navigating a critical period defined by two distinct narratives: a looming legal verdict and a resurgent pharmaceutical pipeline. The stock, trading around €40.60, has nearly doubled over the past twelve months, yet analysts remain divided on its path forward as these parallel stories unfold.

The company’s pharmaceutical division, grappling with stagnant sales ahead of the patent expiry for blockbuster Xarelto, just received a significant boost. Full results from the pivotal OCEANIC-STROKE trial for the stroke prevention drug asundexian have been published in the New England Journal of Medicine. The Phase III study involved 12,327 patients across 37 countries who had previously suffered a stroke or transient ischemic attack. Data showed a clear benefit: 6.2% of patients on asundexian suffered a subsequent stroke, compared to 8.4% on a placebo, marking a significant 26% reduction. Serious cardiovascular events fell by 17%.

Crucially, the drug’s novel mechanism—inhibiting the Factor XIa protein to prevent harmful clots without broadly impairing the body's natural bleeding control—proved its promise. The study reported no associated increase in bleeding risk, a major advantage over existing therapies. This marks a strategic comeback for Bayer’s cardiology ambitions exactly three years after halting the sister OCEANIC-AF trial for lack of efficacy. Management plans to submit the data to global regulators, with further strategic details expected at the virtual Annual Stockholders' Meeting on April 24.

While this clinical progress builds long-term value, a more immediate catalyst is on the horizon from the United States Supreme Court. A landmark ruling on the glyphosate litigation is expected by the end of June. A favorable decision for the Leverkusen-based conglomerate would remove a massive overhang that has long pressured the stock’s risk assessment.

Amid these developments, analysts are recalibrating their models. Deutsche Bank recently took a dramatic step, more than doubling its price target on Bayer shares from €23 to €43, though it maintained a "Hold" rating. The bank’s optimism is partly rooted in the upcoming first-quarter report on May 12, for which it forecasts 3.6% organic sales growth, driven by a stabilizing market for crop protection and seeds in the Crop Science division.

The broader analyst consensus currently sees a fair value of approximately €47 per share. Some institutions are more bullish; UBS recently reaffirmed a "Buy" recommendation with a €52 target. Despite the year's powerful rally of over 94%, the stock currently trades just below its 50-day moving average of €41.19 and remains about 19% above its long-term 200-day line, reflecting persistent investor caution even as the company's market capitalization nears €40 billion.

The coming weeks will test whether Bayer’s operational recovery and pipeline promise can finally outweigh the legal uncertainty that has shadowed it for years.